MBCProject_1819_T2B_RNA
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208899 | — | — | 0.911 |
| 2 | ERR4976618 | — | D | 0.906 |
| 3 | ERR4976617 | — | D | 0.905 |
| 4 | SRR8942978 | — | — | 0.894 |
| 5 | AUR-AG0J-TTP1-A-1-0-R-A741-41 | — | D | 0.889 |
| 6 | SRR8613700 | — | D | 0.883 |
| 7 | be8d8236-4ebc-46de-a4fd-a901fec1cdce | — | — | 0.883 |
| 8 | SAMN03290886 | — | — | 0.870 |
| 9 | SRR25043622 | — | — | 0.868 |
| 10 | SRR2932840 | — | — | 0.865 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.050 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.020 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |